Turkey to India Pharmaceutical Import

The pharmaceutical trade corridor between Turkey and India has experienced significant growth over the past decade. In 2022, the total import value of pharmaceutical products from Turkey to India was approximately $245.2 million USD, with 782 shipments facilitated by 50 Turkish suppliers to 26 Indian buyers. This robust trade relationship underscores the increasing integration of Turkey's pharmaceutical industry into India's healthcare sector.

A notable development in this corridor is the dominance of specific products. Metformin and Vildagliptin, both essential in diabetes management, accounted for 99.9% of the total import value, highlighting the critical role of these medications in India's therapeutic landscape. The average shipment value stood at $314,000 USD, indicating a preference for bulk imports of these high-demand drugs.

Turkey's pharmaceutical exports to India are concentrated in a narrow product range, primarily Metformin and Vildagliptin. This specialization suggests that Turkish manufacturers have established a strong foothold in the production of these medications, leveraging their manufacturing capabilities to meet India's substantial demand. The limited diversification in product categories may be attributed to Turkey's strategic focus on these high-demand drugs, aligning with India's therapeutic needs.

Between 2024 and 2026, the pharmaceutical trade between Turkey and India has been influenced by several key developments. The Central Drugs Standard Control Organisation (CDSCO) has implemented policy changes to streamline the import process, enhancing efficiency and reducing lead times for pharmaceutical imports. Additionally, trade agreements between the two nations have been strengthened, fostering a more conducive environment for pharmaceutical exchanges. Regulatory harmonization efforts have also been undertaken to align standards, facilitating smoother market access for Turkish pharmaceutical products in India.

IMPORT_REGULATORY

For Turkish pharmaceutical companies aiming to export to India, obtaining registration from the Central Drugs Standard Control Organisation (CDSCO) is mandatory. The process involves several key steps:

1. Application Submission: Companies must register on the CDSCO's SUGAM portal, providing details about the applicant and the products intended for import.

2. Document Submission: Essential documents include the applicant's identity and address proofs, a copy of the site registration for Bioavailability (BA) or Bioequivalence (BE) studies, and an undertaking granted by a government authority for the registration of tests, drugs, or medical devices.

3. Verification and Approval: Upon submission, the application undergoes verification by CDSCO officials. This may involve site inspections and consultations with subject-matter experts to assess the safety and efficacy of the products.

4. License Issuance: If the products meet the required standards, CDSCO grants the necessary licenses, authorizing the import and distribution of the pharmaceutical products in India.

The entire process can take several months, depending on the complexity of the products and the completeness of the submitted documentation.

India requires that foreign manufacturing sites adhere to Good Manufacturing Practices (GMP) standards to ensure the quality and safety of imported pharmaceutical products. Manufacturers must obtain WHO prequalification, which involves a rigorous evaluation of manufacturing facilities, quality control systems, and compliance with international standards. The CDSCO conducts inspections to verify adherence to these standards, ensuring that products imported into India meet the necessary quality benchmarks.

To import pharmaceutical products into India, Turkish companies must prepare and submit several key documents:

1. Import License (Form 10): This license authorizes the import of specific pharmaceutical products into India.

2. Registration Certificate: Issued by CDSCO, this certificate confirms that the imported products are approved for sale and distribution in India.

3. No Objection Certificate (NOC): This certificate is required for the import of certain products, indicating that there are no objections to their importation.

4. Test License: For products intended for testing or research purposes, a test license is necessary.

5. Customs Procedures: Compliance with Indian customs procedures is essential, including proper labeling, packaging, and documentation to facilitate smooth clearance of goods at Indian ports.

IMPORT_TRENDS

The pharmaceutical imports from Turkey to India are predominantly focused on specific therapeutic areas, particularly diabetes management. Metformin and Vildagliptin, both critical in the treatment of diabetes, constitute the vast majority of imports, indicating a targeted approach by Turkish manufacturers to meet India's substantial demand in this area. This concentration suggests that Turkish pharmaceutical companies have developed specialized expertise and manufacturing capabilities in these products, aligning with India's therapeutic needs.

While the current trade is heavily concentrated on Metformin and Vildagliptin, there is potential for the introduction of innovative and specialty pharmaceutical products from Turkey to India. Turkey's pharmaceutical industry has been recognized for its advancements in drug development and manufacturing processes. Introducing novel formulations and advanced therapies could address unmet medical needs in India, particularly in areas where domestic production is limited. However, this would require navigating the complex regulatory landscape and ensuring compliance with CDSCO standards.

India's substantial imports of pharmaceutical products from Turkey are driven by several factors:

1. Patent Protection: Turkey's pharmaceutical products, such as Metformin and Vildagliptin, may be under patent protection, preventing domestic manufacturers in India from producing generic versions.

2. Technology Gaps: Turkey's advanced manufacturing technologies and expertise in specific pharmaceutical products fill gaps in India's domestic production capabilities.

3. Quality Requirements: Turkey's adherence to international quality standards, including GMP and WHO prequalification, ensures that imported products meet the high-quality expectations of the Indian market.

4. Disease Burden: The high prevalence of diabetes in India creates a significant demand for effective treatments, driving imports of medications like Metformin and Vildagliptin.

IMPORT_POLICY

India's import tariff structure for pharmaceutical formulations includes several components:

1. Most Favored Nation (MFN) Tariff Rates: These rates are applied to imports from countries with which India has agreed upon tariff schedules under the World Trade Organization (WTO).

2. Basic Customs Duty (BCD): This is the primary duty levied on imported goods, including pharmaceutical products. The rate can vary depending on the product category and prevailing government policies.

3. Integrated Goods and Services Tax (IGST): IGST is applicable on imported goods and is calculated based on the value of the goods plus applicable customs duties.

4. Health Cess: A health cess is imposed on certain imported pharmaceutical products to fund health-related initiatives within the country.

These tariffs and taxes are subject to change based on government policies and international trade agreements.

As of March 2026, there is no specific Free Trade Agreement (FTA) between India and Turkey that offers preferential duty rates for pharmaceutical imports. Both countries are members of the World Trade Organization (WTO), which provides a framework for trade relations. Additionally, India is a member of the Regional Comprehensive Economic Partnership (RCEP), which includes several Asian countries. However, Turkey is not a member of RCEP, and thus, Indian pharmaceutical imports from Turkey do not benefit from RCEP-related preferential duty rates.

India's patent regime, particularly Section 3(d) of the Indian Patents Act, aims to prevent evergreening of patents by disallowing patents on new forms of known substances unless they result in enhanced efficacy. This provision can impact the patentability of certain pharmaceutical products imported from Turkey. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential drugs in India, including imported pharmaceuticals, to ensure affordability. Imported drugs may be subject to price controls, which can affect the pricing strategies of Turkish pharmaceutical companies.

IMPORT_LOGISTICS

Pharmaceutical products from Turkey to India are primarily transported via sea routes, utilizing major ports such as Istanbul and Mersin in Turkey, and Mumbai and Chennai in India. The typical transit time for sea shipments ranges from 20 to 30 days, depending on the specific ports and shipping conditions. Air freight is also utilized for time-sensitive deliveries, with transit times of approximately 5 to 7 days. The reliability of these routes is generally high, but can be affected by factors such as weather conditions and geopolitical events.

In Turkey, major export ports handling pharmaceutical shipments include Istanbul and Mersin. These ports are equipped with modern facilities to handle pharmaceutical exports efficiently. In India, key import ports include Mumbai and Chennai, which have established infrastructure for handling pharmaceutical imports.